0.3894

10.53% 0.0371

After Hours: .37 -0.0194 -4.98%

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $0.3894, with a volume of 1.56M. It is up +10.53% in the last 24 hours and down -19.88% over the past month. X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$0.3523

Open:

$0.3642

24h Volume:

1.56M

Relative Volume:

0.68

Market Cap:

$60.00M

Revenue:

Net Income/Loss:

$-101.17M

P/E Ratio:

-0.3744

EPS:

-1.04

Net Cash Flow:

$-96.57M

1W Performance:

+14.39%

1M Performance:

-19.88%

6M Performance:

-56.88%

1Y Performance:

-49.43%

1-Day Range:

$0.3467

$0.3916

1-Week Range:

$0.3316

$0.3916

52-Week Range:

$0.2612

$1.60

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

143

Twitter

@x4pharma

Next Earnings Date

2024-11-13

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	0.3894	60.00M	0	-101.17M	-96.57M	-1.04
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

Nov 27, 2024

Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference - Business Wire

Nov 27, 2024

Nov 26, 2024

SEC Form 4 filed by CEO, President Rodriguez Raul R - Quantisnow

Nov 26, 2024

X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference - The Manila Times

Nov 26, 2024

X4 Pharmaceuticals to Present at Piper Sandler Healthcare Conference | XFOR Stock News - StockTitan

Nov 26, 2024

Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc. - Quantisnow

Nov 26, 2024

Nov 25, 2024

ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times

Nov 25, 2024

Layoff Tracker: Sonata Therapeutics Laying Off 20 Employees, Changing Leadership - BioSpace

Nov 22, 2024

Nov 21, 2024

FDA approves cancer drug developed by B.C.'s Zymeworks - Business in Vancouver

Nov 21, 2024

Atenolol Global Market 2024 – Top Manufacturers, Latest Trends, Future Prospects And Outlook By 2033 - WhaTech

Nov 21, 2024

B. Riley Predicts Increased Earnings for X4 Pharmaceuticals - Defense World

Nov 21, 2024

Nov 20, 2024

Spotlight On 3 US Penny Stocks With At Least $60M Market Cap - Simply Wall St

Nov 20, 2024

B. Riley Expects Stronger Earnings for X4 Pharmaceuticals - MarketBeat

Nov 20, 2024

Top 10 pharma companies in India by market cap [2024] - Forbes India

Nov 20, 2024

Benzodiazepine Drugs Market Overview: Industry Insights, Demand Trends, Competitive Landscape, and Key Inno... - WhaTech

Nov 20, 2024

Nov 19, 2024

X4 Pharmaceuticals CEO Ragan Paula sells $12,583 in stock - Investing.com

Nov 19, 2024

Chronic Pain Market Set for Steady Growth with 4% CAGR Driven by Drugs and Devices | Future Market Insights, Inc. - GlobeNewswire

Nov 19, 2024

Nov 18, 2024

10 Biggest Biotechnology Companies - Investopedia

Nov 18, 2024

HC Wainwright Predicts Lower Earnings for X4 Pharmaceuticals - MarketBeat

Nov 18, 2024

Nov 15, 2024

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

RFK Jr vow to purge FDA sets up collision with Big Pharma - Reuters

Nov 15, 2024

Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary - Fast Company

Nov 15, 2024

Nov 14, 2024

Earnings call: X4 Pharmaceuticals reports progress in CN treatment By Investing.com - Investing.com Nigeria

Nov 14, 2024

CANbridge Pharmaceuticals Inc. (HKG:1228) Not Doing Enough For Some Investors As Its Shares Slump 28% - Simply Wall St

Nov 14, 2024

XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia… - Zacks Small Cap Research

Nov 14, 2024

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer's Pipeline - Quantisnow

Nov 14, 2024

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference - Yahoo Finance

Nov 14, 2024